C. Melief, T. Van-hall, R. Arens, F. Ossendorp, and S. H. Van-der-burg, Therapeutic cancer vaccines, J Clin Invest, vol.125, pp.3401-3412, 2015.

J. Pol, A. Sevko, J. Heide, M. Dams, A. Rupp et al., Trial watch: peptide-based anticancer vaccines, Oncoimmunology, vol.4, pp.974411-974424, 2015.

M. S. Bijker, S. Van-den-eeden, K. L. Franken, C. Melief, R. Offringa et al., CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J Immunol, vol.179, pp.5033-5040, 2007.

R. A. Rosalia, V. Rebmann, J. Lemaoult, C. Rodriguez, P. A. Horn et al., Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation, Eur J Immunol, vol.43, pp.2554-2565, 2013.

H. Zhang, H. Hong, D. Li, S. Ma, Y. Di et al., Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4 + T Cells, J Biol Chem, vol.284, pp.9184-9191, 2009.

H. Wada, M. Isobe, K. Kakimi, Y. Mizote, S. Eikawa et al., Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen, J Immunother, vol.37, pp.84-92, 2014.

G. G. Kenter, M. Welters, A. Valentijn, M. Lowik, D. Berendsvan-der-meer et al., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N Engl J Med, vol.361, pp.1838-1847, 2009.

P. A. Ott, Z. Jacobs, B. Marwick, R. Fullagar, L. Wallis et al., An immunogenic personal neoantigen vaccine for patients with melanoma, Nature, vol.547, pp.217-221, 2017.

J. Ohtake, T. Ohkuri, Y. Togashi, H. Kitamura, K. Okuno et al., Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine, Immunol Lett, vol.161, pp.20-30, 2014.

K. Masuko, D. Wakita, Y. Togashi, T. Kita, H. Kitamura et al., Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy, Immunol Lett, vol.163, pp.102-112, 2015.

P. Daftarian, M. Mansour, A. C. Benoit, B. Pohajdak, D. W. Hoskin et al., Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion, Vaccine, vol.24, pp.5235-5244, 2006.

J. Alexander, J. Sidney, S. Southwood, J. Ruppert, C. Oseroff et al., Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides, Immunity, vol.1, pp.751-761, 1994.

M. Dosset, Y. Godet, C. Vauchy, L. Beziaud, Y. C. Lone et al., Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor, Clin Cancer Res, vol.18, pp.6284-6295, 2012.

Y. Godet, A. Moreau-aubry, Y. Guilloux, V. Vignard, A. Khammari et al., MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency, J Exp Med, vol.205, pp.2673-2682, 2008.

M. Bobinet, V. Vignard, L. Florenceau, F. Lang, N. Labarriere et al., Overexpression of meloe gene in melanomas is controlled both by specific transcription factors and hypomethylation, PLoS One, vol.8, p.75421, 2013.

D. Carbonnelle, V. Vignard, D. Sehedic, A. Moreau-aubry, L. Florenceau et al., The melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences, PLoS One, vol.8, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-01726993

A. Rogel, V. Vignard, M. Bobinet, N. Labarriere, and F. Lang, A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination, Cancer Immunol Immunother, vol.60, pp.327-337, 2011.

M. Bobinet, V. Vignard, A. Rogel, A. Khammari, B. Dreno et al., MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients, PLoS One, vol.7, p.51716, 2012.

Y. Godet, J. Desfrançois, V. Vignard, D. Schadendorf, A. Khammari et al., Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, Eur J Immunol, vol.40, pp.1786-1794, 2010.

A. Pajot, P. A. Van-veelen, A. H. De-ru, P. J. Hensbergen, K. Mizuno et al., A mouse model of human adaptive immune functions: hLA-A2.1-/HLADR1-transgenic H-2 class I-/class II-knockout mice, Eur J Immunol, vol.34, pp.3060-3069, 2004.

T. Serwold, F. Gonzalez, J. Kim, R. Jacob, and N. Shastri, ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum, Nature, vol.419, pp.480-483, 2002.

O. 'brien, C. Flower, D. R. Feighery, and C. , Peptide length significantly influences in vitro affinity for MHC class II molecules, Immunome Res, vol.4, pp.6-7, 2008.

H. A. Chapman, Endosomal proteases in antigen presentation, Curr Opin Immunol, vol.18, pp.78-84, 2006.

N. D. Rawlings, A. J. Barrett, and R. Finn, Twenty years of the MEROPSdatabase of proteolytic enzymes, their substrates and inhibitors, Nucleic Acids Res, vol.44, pp.343-350, 2016.

J. M. Chauvin, P. Larrieu, G. Sarrabayrouse, A. Prevost-blondel, R. Lengagne et al., HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells, J Immunol, vol.188, pp.2102-2110, 2012.

E. Martinuzzi, J. Hackbarth, P. A. Schneider, K. L. Peterson, X. W. Meng et al., acDCs enhance human antigen-specific T-cell responses, Blood, vol.118, pp.2128-2137, 2011.

L. Rangan, J. Galaine, R. Boidot, M. Hamieh, M. Dosset et al., Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice, Oncotarget, vol.8, pp.48959-48971, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01699821

G. G. Kenter, M. Welters, A. Valentijn, M. Lowik, D. Berendsvan-der-meer et al., Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity, Clin Cancer Res, vol.14, pp.169-177, 2008.